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Background. Despite increasing evidence of the development of Plasmodium vivax chloroquine (CQ) resistance, there have 
been no trials comparing its efficacy with that of artemisinin-based combination therapies (ACTs) in Latin America.
Methods. This randomized controlled trial compared the antischizontocidal efficacy and safety of a 3-day supervised treatment 
of the fixed-dose combination artesunate-amodiaquine Winthrop® (ASAQ) versus CQ for treatment of uncomplicated P. vivax infec-
tion in Manaus, Brazil. Patients were followed for 42 days. Primary endpoints were adequate clinical and parasitological responses 
(ACPR) rates at day 28. Genotype-adjustment was performed.
Results. From 2012 to 2013, 380 patients were enrolled. In the per-protocol (PP) analysis, adjusted-ACPR was achieved in 100% 
(165/165) and 93.6% (161/172) of patients in the ASAQ and CQ arm (difference 6.4%, 95% CI 2.7%; 10.1%) at day 28 and in 97.4% 
(151/155) and 77.7% (129/166), respectively (difference 19.7%, 95% CI 12.9%; 26.5%), at day 42. Apart from ITT D28 assessment, 
superiority of ASAQ on ACPR was demonstrated. ASAQ presented faster clearance of parasitaemia and fever. Based on CQ blood 
level measurements, CQ resistance prevalence was estimated at 11.5% (95% CI: 7.5-17.3) up to day 42. At least one emergent adverse 
event (AE) was recorded for 79/190 (41×6%) in the ASAQ group and for 85/190 (44×7%) in the CQ group. Both treatments had 
similar safety profiles.
Conclusions. ASAQ exhibited high efficacy against CQ resistant P. vivax and is an adequate alternative in the study area. Studies 
with an efficacious comparator, longer follow-up and genotype-adjustment can improve CQR characterization.  
Clinical Trials Registration. NCT01378286.
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There were an estimated 214 million malaria episodes and 438 
000 related deaths in 2015 [1]. Plasmodium vivax is the malar-
ia-causing parasite species with the widest geographical distri-
bution, resulting in 2.85 billion people at risk [2]. Studies from 
all P. vivax endemic areas demonstrate that this infection can 
progress to have severe and fatal outcomes [3, 4], rendering the 
long-held belief that P. vivax is benign as no longer valid [5].
Resistance to antimalarials is a major barrier for 
case-management and control of transmission [6, 7] and 
requires constant monitoring. For more than 60 years, the 
mainstay of P. vivax treatment has been a combination of 
chloroquine (CQ) with primaquine (PQ) as an antirelapse 
drug [8, 9]. This combination’s synergistic schizontocidal 
effect, which is associated with the parasite’s usually lower 
biomass and shorter duration of gametocytes presence 
compared with those of Plasmodium falciparum, may have 
contributed to slower development of CQ resistance in P. 
vivax [9]. However, there has been an increasing number of 
reports of CQ resistance (CQR) in regions where this par-
asite is endemic [10–12], especially in Southeast Asia and 
the Pacific region [13–15], where 5 countries have already 
adopted artemisinin-based combination therapies (ACTs). 
these therapies provide fast parasite clearance and prevent 
recrudescences [16] as first-line treatment for P. vivax [1]. 
In Latin America, where P. vivax is the most prevalent spe-
cies causing malaria [1] despite recent evidence of CQR [11, 
17–20], no studies comparing the efficacy of ACTs to that of 
CQ have been reported.
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The combination of artesunate–amodiaquine (ASAQ) against 
P. falciparum has been adopted in many countries and is one of 
the World Health Organization (WHO) prequalified antimalari-
als. The ASAQ fixed-dose combination (FDC) tested in this study 
(artesunate–amodiaquine Winthrop, or ASAQ Winthrop) was 
codeveloped by DNDi and Sanofi. This formulation was shown 
to result in better compliance and reduced risk of emergence of 
P. falciparum resistance when compared with loose-dose combi-
nations and coblisters [21, 22]. We conducted this clinical trial in 
order to evaluate the efficacy and safety of the ASAQ FDC com-
pared with that of CQ against uncomplicated P. vivax infection.
METHODS
Study Site
Our study was undertaken at Fundação de Medicina Tropical 
Dr. Heitor Vieira Dourado (FMT-HVD), Manaus, in the 
Brazilian Western Amazon region. Malaria transmission is 
restricted to rural areas, and P.  vivax causes around 90% of 
malaria cases [23]. Antimalarials are only provided in health 
units after diagnostic confirmation of infection. National 
guidelines recommend CQ (total dose of 25 mg/kg over 3 days) 
and PQ (0.5 mg/kg/day over 7 days) for P. vivax infection treat-
ment and artemether–lumefantrine or artesunate–mefloquine 
for P. falciparum [24]. Studies showed therapeutic failure rates 
as high as 10% with CQ monotherapy for P. vivax in 2005 [17].
Study Design
This was an open-label, randomized, noninferiority, controlled 
trial that compared the efficacy and safety of ASAQ (Winthrop; 
Sanofi, Morocco) and CQ (Farmanguinhos, Brazil) for treat-
ment of uncomplicated P.  vivax blood stage infection. The 
study was based on the WHO antimalarial drug efficacy proto-
cols modified for P. vivax [25, 26]. Patients were followed up for 
42 days to assess drug efficacy and safety.
The ethics review board of FMT-HVD (0426/2011) and the 
National Brazilian Committee of Ethics (16532/2011) approved 
the study. All adult patients and legal guardians of children pro-
vided written informed consent. The protocol is available in the 
Supplementary Materials.
Patients
Individuals aged >6  months with a body weight >5  kg with 
slide-confirmed P.  vivax monoinfection, parasite density 
between 250 and 100 000 parasites/µL, and axillary temperature 
≥37.5°C or history of fever in the last 48 hours were considered 
eligible. Exclusion criteria included pregnant or breast-feeding 
women; plan of leaving the study area in the following 42 days; 
known hypersensitivity to 1 of the investigational products; 
blurred vision suggesting retinopathy; presence of at least 1 
severe criterion of malaria; known severe concomitant or under-
lying disease; and women of childbearing potential unwilling to 
use an effective contraceptive method during the study.
Procedures, Randomization, and Concealment
Enrolled patients were randomly assigned to 1 of the treatment 
arms by a study nurse through a computer-generated list that 
linked each patient’s study number to an opaque zone, thus, 
concealing the assigned treatment arm. Neither the study doc-
tors nor the laboratory personnel responsible for reading the 
slides and the polymerase chain reaction (PCR) test had access 
to patients’ allocation during the study.
ASAQ was administered as a fixed-dose combination with 
3 oral formulations (25/67.5 mg, 50/135 mg, 100/270 mg) and 
CQ as 150-mg tablets. Dosing was based on established weight 
bands for each drug (Supplementary Table  1). Study nurses 
supervised all dosing at enrollment and 24 and 48 hours after. 
When necessary, tablets were dissolved in water and adminis-
tered orally using a syringe to ensure proper dosing to children. 
Patients were followed on an outpatient basis. PQ was withheld 
until day 42 or at day of recurrence. Recurrences during fol-
low-up were treated with fixed-dose artesunate–mefloquine 
combination (Farmanguinhos, Brazil). The dose was adminis-
tered a second time if vomiting occurred within 30 minutes.
Visits for clinical and microscopic assessments were sched-
uled on days 1, 2, 3, 7, 14, 28, and 42 after enrollment. Laboratory 
blood assessments (total blood cell count, bilirubin, glycemia, 
aspartate aminotransferase, alanine aminotransferase [ALT], 
and creatinine) were performed at enrollment and repeated 
on day 7 and day 28. Electrocardiograms were performed at 
enrollment, day 2, and day 28 for all participants aged >10 years 
and evaluated by a cardiologist. Blood samples were collected 
on day 7 and day of recurrence for CQ and desetylchloroquine 
(DCQ) blood assays, measured using high-performance liquid 
chromatography as previously described [27]. The sum of CQ 
and DCQ blood levels was used to classify parasites as sensitive 
or resistance based on the 100-ng/mL cutoff level, as previously 
established [12, 26, 28]. Technical problems with sample storage 
and collection, consisting of insufficient volume of blood for the 
analyses, prevented measurement of day 7 blood levels of AQ.
Two experienced technicians examined microscopic blood 
smears. Parasite density was calculated using the white cell 
count from the nearest total blood cell count (usually from 
enrollment, day 7, or day 28) [29].
Molecular Analyses
Real-time PCR was performed on filter-paper samples from 
enrollment or recurrences to confirm P.  vivax monoinfection 
according to described protocols [30]. For the genotyping pro-
cedures for comparing day 0 and recurrence samples, 3 highly 
polymorphic gene regions were chosen according to diversity 
and discriminatory potential in the region, namely, msp1F3, 
MS2, and MS8 [31–34]. As there is no standard recommenda-
tion for classifying P. vivax recurrences due to difficulties dis-
tinguishing reinfection, recrudescence, and relapse [35, 36], we 
adapted the classification method recommended by WHO for 
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P. falciparum [25]. For each recurrence, samples were classified 
as homologous if at least 1 allele for each loci investigated was 
detected in both paired samples and as heterologous if all alleles 
for a given marker were different. A  recurrent homologous 
P. vivax episode could derive either from a recrudescent-resist-
ant parasite or from a dormant liver stage. For this study, we 
chose to treat these events as treatment failures after correction. 
Further details on the molecular characterization are provided 
in the Supplementary Materials.
Statistical Analyses and Sample Calculation
We assumed a 90% efficacy rate for CQ within 28 days [17] and 
95% efficacy for ASAQ [37]. The noninferiority margin was 
defined at 5%, considering alpha at 2.5% for the unilateral test 
and power of 90%, a sample size of 145 individuals per arm, 
increased to 190 after adding 15% loss to follow-up and 10% 
risk of mixed infections.
The primary endpoint was genotype-adjusted adequate cure 
and parasitological response (ACPR) at day 28 for the per-protocol 
(PP) population. Secondary endpoints, performed in both the PP 
and intention-to-treat (ITT) populations, included crude ACPR on 
day 28 and ACPR on day 14 and day 42, prevalence and incidence 
of positive asexual parasitemia and gametocyte carriage, hemoglo-
bin changes from baseline, and incidence of adverse events (AEs).
Noninferiority was demonstrated if the lower bound of the 
95% confidence interval (CI) of the risk difference between the 
2 arms was greater than −0.05 in the PP population populations. 
The CIs were calculated using normal approximation, with 
continuity correction in the Wald limits applied in the case of 
empty cells [38]. If noninferiority was shown, a 2-sided Fisher 
exact test to assess superiority was performed in the ITT popu-
lation. This analysis was performed despite not being described 
in the protocol-following recommendation [39] and due to the 
large difference observed. Both the PP and ITT are presented.
Figure 1. Flowchart of the study. *Some patients had more than 1 reason for exclusion. Abbreviations: ASAQ, artesunate–amodiaquine; CQ, chloroquine; PCR, polymerase 
chain reaction; PP, per protocol; P. vivax, Plasmodium vivax. 
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Time to recurrence was assessed by survival curves using the 
Kaplan-Meier estimator and log-rank tests. The proportion of 
patients with negative blood slides for both asexual and sexual par-
asites and fever clearance was analyzed at days 1, 2, and 3. A general 
estimating equation (GEE) model [40] was used to compare per-
son-week gametocyte densities during follow-up; this consisted of a 
univariate analysis with robust standard errors, with the number of 
gametocyte-positive slides per individual per week as the outcome.
Anemia was graded according to WHO references [41]. 
Neutropenia and elevation of ALT were considered AEs of spe-
cial interest [42–44]. An independent data monitoring com-
mittee comprised of 3 renowned experts reviewed the study 
protocol and evaluated the results of efficacy and safety analy-
ses. An additional analysis was performed only for the CQ arm 
to investigate a possible association between delayed parasite 
clearance (>72 hours) as the dependent variable and risk of 
recurrence, the outcome variable, using logistic regression.
RESULTS
Patients were enrolled between January 2012 and June 2013 
(Figure 1). Most patients were adult males and resided in the 
nonactive transmission Manaus urban area (Table 1).
Noninferiority was demonstrated (97.5% CI lower 
bound  =  2.74) as genotype-adjusted ACPR rates at day 28 
of 100% (165/165) for ASAQ and 93.6% (161/172) for CQ. 
Although superiority of ASAQ was not demonstrated on day 28 
in the ITT population (P = .345), it was demonstrated in the PP 
population and on day 42 for both populations (Tables 2 and 3; 
Figure 2). The difference was larger between day 28 and day 42.
Through genotype classification, 64.8% (34/54) of the CQ 
arm recurrences (ITT population) were homologous compared 
with half (3/6) in the ASAQ arm (Figure 3A and Table 3). CQ/
DCQ blood levels on the day of recurrence were measured for 
48 of 54 patients, with 19 being >100 ng/mL, resulting in a CQR 
prevalence of 11.5% (95% CI, 7.5–17.3). This result was further 
corroborated by both homologous (14/34) and heterologous 
(5/6) recurrences emerging in the circulation, with CQ/DCQ 
blood levels as high as 533 ng/mL (Figure 3B).
Parasitemia clearance was faster, and the proportion of patients 
clearing fever at day 1 was higher for ASAQ (Tables 2 and 3). 
Table 1. Demographic and Disease Characteristics at Baseline in the In-
tention-to-Treat Population
Variable
Artesunate–
Amodiaquine (n = 189) Chloroquine (n = 190)
Male 136 (72.0%) 144 (75.8%)
Age, y 35.7 (1–68; 16·4) 34.7 (1–74; 15·9)
<6 7 (3.7%) 7 (3.7%)
6–14 10 (5.3%) 14 (7.4%)
≥14 172 (91.0%) 169 (88.9%)
Weight, kg 68.8 (8.5–117.9; 18.8) 68.4 (9.5–111.0; 20.3)
Concomitant illness 25 (13.2%) 28 (14.7%)
Residing in Manaus urban 
area
170 (89.5%) 174 (91.6%)
Temperature (°C) 37.2 (34.9–40.1; 1.3) 37.1 (35.0–40.0; 1.3)
Temperature ≥37.5°C 85 (45.0%) 77 (40.5%)
Geometric mean parasite 
density per μL (95% 
confidence interval)
1746 (1475–2068) 1643 (1412–1912)
Positive gametocytemia 105 (55.6%) 114 (60.0%)
Hemoglobin (g/dL) 13.3 (7.3–18.3; 1.9) 13.2 (7.8–17.3; 1.7)
Anemia 93 (48.9%) 83 (43.7%)
Data are expressed as percentage or mean (range; standard deviation), unless specified 
otherwise.
Table 2. Adequate Clinical and Parasitological Response (ACPR) by Time 
Point for the Per-Protocol Population
Variable
Artesunate– 
Amodiaquine, 
n = 165 (%)
Chloroquine, 
n = 172 (%)
Difference (95% 
Confidence 
Interval) P value
Day 28
Genotype-adjusted 
ACPR
165 (100) 161 (93.6) 6⋅4% (2⋅7–10⋅1) ⋅001
Total failures 0 11 (6.4)
 Late clinical failure 0 4 (2.3)
 Late parasitological 
failure
0 7 (4.1)
Genotype classification of failures
 Homologous 0 10 (5.8)
 Heterologous 0 2 (1.2)
 Indeterminate 0 1 (0⋅6)
Unadjusted ACPR 165 (100.0) 159 (92.4) 7⋅6% (3⋅6–11⋅5) <⋅001
Total failures 0 13 (7.5)
 Late clinical failure 0 4 (2.3)
 Late parasitological 
failure
0 9 (5.2%
Day 42 n = 155 n = 166
Genotype-adjusted 
ACPR
151 (97.4) 129 (77.7) 19⋅7% (12⋅9–26⋅5) <⋅001
Total failures 4 (2.6) 37 (22.3)
 Late clinical failure 2 (1.3) 14 (8.4)
 Late parasitological 
failure
2 (1.3) 23 (13.9)
Genotype classification of failuresa
 Homologous 3(1.9) 31 (20.1)
 Heterologous 2 (1.3) 7 (4.2)
  Indeterminate  
polymerase 
chain reaction
1 (0.7) 6 (3.6)
Unadjusted ACPR 149 (96.1) 122 (73.5) 22⋅6% (15⋅3–30⋅0)<0⋅001
Total failure 6 (3.9) 44 (36.9)
 Late clinical failure 2 (1.3) 17 (10.2)
  Late parasitological-
failure
4 (2.6) 27 (16.3)
Parasite and fever clearance
Parasite cleared  
at day 1
33 (20.0) 4 (2.3) <.001
Parasite cleared  
at day 2
144 (87.3) 77 (44.8) <.001
Parasite cleared  
at day 3
164 (99.4) 138 (80.2) <.001
Fever cleared at day 1164 (99.4) 154 (89.5) <.001
Abbreviation: ACPR, adequate cure and parasitological response.
aGenotyping detailed data available in Table Supplementary S1.
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From day 7, 2.4% of patients treated with ASAQ and 14.7% in 
the CQ group presented with microscopically detected gameto-
cytes during follow-up (P < .001). The GEE model demonstrated 
a lower overall gametocyte-positive density in the ASAQ arm 
compared with that of CQ (4.7 vs 12.2 gametocyte-positive 
slides/100 person-weeks, respectively; P < .001). Risk of develop-
ing gametocytemia after treatment initiation in patients with no 
gametocytes at inclusion (ASAQ, n = 83; CQ, n = 76) was higher 
for CQ (20.2% vs 55.4%; P < 0·001). There was no association 
between delayed parasite clearance and risk of recurrence (odds 
ratio = 1.1; 95% CI, 0.7–1.6; P = .836) in the CQ arm.
There was a relative decrease of hemoglobin (Hb) between 
inclusion and day 7 for all patients (−2.5; standard devia-
tion  =  8.4), with greater reduction observed for ASAQ (−4.2 
[7.4] vs −0.9 [9.0]; P < .001). There was a similar proportion of 
patients who presented with grade 2 or higher anemia at day 
7 (3 [1.6%] vs 2 [1.1%]). At day 28, patients who received CQ 
presented with a higher increase from baseline (0.3 [13.2] vs 3.7 
[12.0]; P = .005). Overall AE rates were similar (Table 4). Severe 
AEs were only observed in the ASAQ arm, none with sequelae.
DISCUSSION
We observed high efficacy of the ASAQ FDC against 
CQ-resistant P. vivax with respect to ACPR and other efficacy 
outcomes. This is the first study to compare the ASAQ combi-
nation with chloroquine against P. vivax infection and the first 
trial to compare an ACT with CQ in Latin America [1].
A remarkable result of this study is the high efficacy of ASAQ 
at day 42 (for which all recurrences occurred after day 40). 
Interpretation of failures occurring after day 28 is complicated 
by the possibility of recurrences being relapses or reinfections [9, 
25]. Despite this caveat, we believe the observed late recurrences 
Table 3. Efficacy Assessments at Day 28 and Day 42 for the Intention-to-Treat Population
Variables
Artesunate– 
Amodiaquine, n = 189 (%) Chloroquine, n = 190 (%)
Difference (95% 
Confidence Interval) P value
Day 28
Genotype-adjusted ACPR 177 (93.7) 172 (90.5) 3.1% (−2⋅3–8⋅5) .345
Total failures 12 (6.3) 18 (9.5)
 Late clinical failure 0 (0.0) 4 (2.1)
 Late parasitological failure 0 (0.0) 7 (3.7)
 Missing data a 12 (6.3) 7 (3.7)
Genotype classification of failures
 Homologous 0 10 (5.8)
 Heterologous 0 2 (1.2)
 Indeterminate 0 1 (0.6)
Unadjusted ACPR 177 (93.7) 170 (89.5) 4.2% (−1.4–9.8) .201
Total failuresa 12 (6.3) 20 (10.5)
 Late clinical failure 0 4 (2.1)
 Late parasitological failure 0 9 (4.7)
Day 42
Genotype-adjusted ACPR 162 (85.7) 136 (71.6) 14.1% (6.0–22.3) .001
Total failures 27 (14.3) 54 (28.4)
 Late clinical failure 2 (1.1) 15 (7.9)
 Late parasitological failure 2 (1.1) 26 (13.7)
 Missing data a 23 (12.2) 13 (6.8)
Genotype classification of failures
 Homologous 3 (1.6) 34 (18.4)
 Heterologous 2 (1.1) 7 (3.7)
 Indeterminate polymerase chain reaction 1 (0.5) 7 (3.7)
Unadjusted ACPR 160 (84.7) 129 (67.9) 16.8% (8.4–25.2) <.001
Total failures 29 (15.5) 61 (32.1)
 Late clinical failure 2 (1.1) 18 (9.5)
 Late parasitological failure 4 (2.1) 30 (15.8)
Parasite and fever clearance
Parasite cleared at day 1 38 (20.1) 9 (4.7) <.001
Parasite cleared at day 2 162 (85.7) 89 (46.8) <.001
Parasite cleared at day 3 184 (97.4) 153 (80.5) <.001
Fever cleared at day 1 184 (97.4) 168 (88.4) <.001
Genotyping detailed data available in Supplementary Table S1.
Abbreviation: ACPR, adequate cure and parasitological response.
aLosses to follow-up and samples with genotype assessment..
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indicate the existence of low-grade resistance to CQ, which would 
suppress but not completely eliminate circulating parasites [12]. 
This is based on 2 important assumptions: very low risk of reinfec-
tion, as most patients (90.5%) resided in urban areas with no active 
malaria transmission [23], and negligible contribution of relapses, 
which usually occur after day 35 in the region [32, 45, 46].
In the absence of PQ administration, the drug’s elimination 
half-life is an important property to be considered against P. vivax 
due to the post-treatment prophylactic effect [9]. Its influence is 
illustrated by 2 trials that compared the ASAQ loose-dose combi-
nation to dihydroartemisinin–piperaquine, an ACT with a longer 
half-life. Lower efficacy against late recurrences of ASAQ [43] was 
not confirmed when PQ was coadministered [44]. This rationale 
is supported by the higher efficacy of CQ in preventing late recur-
rences compared with drugs with shorter half-lives (arthemeter–
lumefantrine) in areas of low prevalence of CQR [47]. Thus, our 
results provide strong evidence of a higher-than-expected CQR 
prevalence because, even though CQ and its metabolites’ half-lives 
are longer, there was a large number of recurrences in the CQ arm.
The genotype-adjusted ACPR rates were measured in 
an attempt to gain a more rigorous case definition of CQR. 
Genotyping has been applied in P. vivax efficacy studies with 
interesting results [35, 36]. However, unlike in P.  falciparum, 
there are no well-defined criteria to differentiate recrudescence 
from reinfection and relapse [25]. PCR correction will not 
necessarily lead to more precise estimation of efficacy in areas 
of low endemicity, where homologous hypnozoites are more 
likely [34].
ASAQ was more effective in clearing patent gametocytemia. 
CQ may take up to 4 days for gametocyte clearance [48]. Studies 
have found an association between prolonged gametocytemia 
and asexual stage recurrence [49]. It is not clear if use of an ACT 
has an effect on reducing transmission.
Hb reduction at day 7 was higher in patients who received 
ASAQ. Possible explanations include higher inflammatory 
response and/or oxidative stress associated with treatment, sup-
pression of the blood marrow by artesunate, and pitting [50, 
51]. The risk of severe anemia after ACT is considered low [52]; 
indeed, there was no severe anemia in our study.
The safety and tolerability of ASAQ FDC were consistent 
with what was found in previous studies that used this combi-
nation in the approved indication “treatment of uncomplicated 
P. falciparum malaria” [42]. Sinus bradycardia occurred without 
symptoms or clinical complications, and there was no differ-
ence regarding  the corrected QT inverval (QTc).
A limitation of our study was the small number of children 
included. This population is at higher risk of treatment failure 
[53, 54], for which age-stratified sampling would be impor-
tant. There was a higher loss to follow-up in the ASAQ arm, 
which had an impact on the efficacy assessment in the ITT 
population. An examination of the notification database did 
not reveal a higher rate of failure among losses. As we were 
not able to assess the pharmacokinetic profile of amodiaquine, 
evaluation of the effect of a longer elimination half-life in 
this population on efficacy against late recurrences was not 
possible.
Figure 2. Kaplan-Meier estimates for time to recurrence. A, Polymerase chain reaction (PCR)–corrected per-protocol (PP) population. B, Crude estimate of PP population. 
C, PCR-corrected intention-to-treat (ITT) population. D, Crude estimate of ITT population. P value from log-rank test. Abbreviations: ASAQ, artesunate–amodiaquine; CQ, 
chloroquine.
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By not coadministering PQ, we were able to estimate CQR, 
which at 11.5%, considering concurrent blood drug levels cri-
terion, is very high. This is important, as patients receiving CQ 
are at higher risk of recurring episodes from resistant parasites 
that arise from either recrudescence or relapse. These findings 
also suggest that the usual methods for measuring CQ efficacy 
are prone to underestimate the true CQR rates. Most studies of 
P. vivax efficacy restrict follow-up to 28 days in order to mini-
mize the contribution of relapses, considering CQ elimination 
half-life. We believe this can result in underestimation of resist-
ance, which, in our study, could be as high as 30% based on the 
risk difference against an efficacious comparator. This difference 
highlights the need to develop better designs and strategies for 
measuring antimalarial efficacy against P. vivax.
CONCLUSIONS
This is the first trial to compare an ACT with CQ as blood 
schizontocidal against P.  vivax in Latin America. We demon-
strated that CQR is underestimated in the region and that a 
change in treatment policy should be considered. Recently 
Plasmodium vivax has received increased attention, requiring 
development of new strategies and tools [55]. The choice of 
an effective schizontocidal drug, therefore, cannot be under-
estimated. Although CQ is still the first-line therapy in most 
endemic countries, resistance is a growing problem, probably 
underestimated because of coadministration with PQ and mis-
classification of recrudescence as relapse. The decision to sub-
stitute CQ for an ACT as the drug of choice for treating P. vivax 
infections is complex and should be based on different factors, 
including the prevalence of CQ-resistant parasites; the current 
treatment adopted for P.  falciparum; efficacy of the partner 
drug; interaction of the ACT with PQ; and the potential impact 
of reducing transmission [13]. In order to establish unified 
treatment recommendations for P.  falciparum and P.  vivax, it 
is necessary to provide a more effective option and reduce the 
risk of treating P. falciparum with CQ due to misdiagnosis [50]. 
We believe that CQ should be replaced by a more efficacious 
Figure 3. A, Genotype of failures in both arms is shown as same (red diamonds) 
or distinct (black dots) genotype according to day of follow-up (lines show the 
median day of failure). B, Chloroquine (CQ)/desetylchloroquine blood levels on the 
day of failure from patients in the CQ arm according to genotype classification (line 
demarks the 100 ng/mL threshold). Abbreviations: CQ, chloroquine; DCQ, desetyl-
chloroquine; DR: day of reccurrence . 
Table 4. Most Frequent Adverse Events Reported in the Safety Population
Variables
Artesunate– 
Amodiaquine, 
n = 190 (%)a
Chloroquine, 
n = 190 (%)
All AEs
Patients with at least 1 event 79 (41.6) 85 (44.7)
Cardiac disorders 35 (18.4) 21 (11.1)
Skin disorders 14 (7.4) 23 (12.1)
Infections and infestations 16 (8.4) 21 (11.1)
Gastrointestinal disorders 16 (8.4) 15 (7.9)
Psychiatric disorders/insomnia 8 (4.2) 12 (6.3)
Drug-related AEsb
Patients with at least 1 of the following: 59 (31.1) 47 (14.7)
Sinus bradycardia 28 (14.7) 11 (5.8)
Pruritus 13 (6.8) 19 (10.0)
Increased ALAT 9 (4.7) 8 (4.2)
Gastritis 8 (4.2) 5 (2.6)
Vomiting 6 (3.2) 5 (2.6)
Insomnia 2 (1.1) 4 (2.1)
Diarrhea 2 (1.1) 0 (0.0)
At least 1 event of special interest 8 (4.2) 9 (4.7)
Increased ALATc 8 (4.2) 8 (4.2)
Neutropeniad 0 1 (0.5)
Serious AEs¶
Patients presenting at least 1 serious AE* 3 (1.6) 0
Vomiting 3 0
Severe gastritis 1 0
Extrapyramidal syndrome 1 0
Only AEs that affected at least 4% in each group are listed. 
Abbreviations: AE, adverse event; ALAT, alanine aminotransferase.
a The patient with mixed infection detected by polymerase chain reaction was included in 
the safety analyses.
b Only events that affected at least 1% of the population in each group are listed.
c ALAT >5 × upper limit of normal (ULN) value, or ALAT >3 × ULN if ALAT was >ULN on 
day 0, or ALAT >3 × ULN associated with total bilirubin >2×ULN. 
d Neutrophil count <400/mm3 in children aged 3 months to 12 years or <750/mm3 in chil-
dren aged >12 years or adults. ¶Events were classified as serious AEs based on the need 
for intravenous medication to alleviate the symptoms. 
*There were no investigational product discontinuation or deaths in the study. Full recovery 
occurred for all AEs.
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alternative in this region and expect policymakers to consider 
these findings in order to define the best strategies to accelerate 
the path toward malaria eradication.
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